UY31581A1 - Derivado 15, 16-metilen-17-(1' - propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene - Google Patents

Derivado 15, 16-metilen-17-(1' - propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene

Info

Publication number
UY31581A1
UY31581A1 UY31581A UY31581A UY31581A1 UY 31581 A1 UY31581 A1 UY 31581A1 UY 31581 A UY31581 A UY 31581A UY 31581 A UY31581 A UY 31581A UY 31581 A1 UY31581 A1 UY 31581A1
Authority
UY
Uruguay
Prior art keywords
oxidoestra
propenil
methylen
ona
derivative
Prior art date
Application number
UY31581A
Other languages
English (en)
Inventor
Frederik Menges
Jan Huebner
Hans-Peter Muhn
Steffen Borden
Katja Prelle
Sven Ring
Rolf Bohlmann
Ulrich Klar
Thomas Frenzel
Joachim Kuhnke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31581(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31581A1 publication Critical patent/UY31581A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Derivados de 15,16-metilen-17-(1`-propenil) -17-3` -oxidestra-4-en -3 -ona que tienen la formula química general I , donde z se selecciona del grupo que comprende oxígeno, dos átomos de hidrogeno , NOR y NNHSO2R donde R es hidrogeno, C1-C10-alquilo o C7-C20-aralquilo, R4 se selecciona del grupo que comprende hidrogeno y halogeno.
UY31581A 2007-12-29 2008-12-26 Derivado 15, 16-metilen-17-(1' - propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene UY31581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063496A DE102007063496A1 (de) 2007-12-29 2007-12-29 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
UY31581A1 true UY31581A1 (es) 2009-08-03

Family

ID=40585540

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31581A UY31581A1 (es) 2007-12-29 2008-12-26 Derivado 15, 16-metilen-17-(1' - propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene

Country Status (24)

Country Link
US (1) US8623850B2 (es)
EP (1) EP2238148B1 (es)
JP (1) JP5600070B2 (es)
KR (1) KR20100110348A (es)
CN (1) CN101918427B (es)
AR (1) AR069963A1 (es)
AU (1) AU2008342915A1 (es)
BR (1) BRPI0821667A2 (es)
CA (1) CA2710486A1 (es)
CL (1) CL2008003921A1 (es)
CO (1) CO6321233A2 (es)
CR (1) CR11544A (es)
DE (1) DE102007063496A1 (es)
DO (1) DOP2010000202A (es)
EA (1) EA201001011A1 (es)
EC (1) ECSP10010317A (es)
ES (1) ES2397970T3 (es)
IL (1) IL206383A0 (es)
PA (1) PA8809801A1 (es)
PE (1) PE20091181A1 (es)
TW (1) TW200938205A (es)
UY (1) UY31581A1 (es)
WO (1) WO2009083271A1 (es)
ZA (1) ZA201005398B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3410880A1 (de) * 1984-03-21 1985-10-03 Schering AG, Berlin und Bergkamen, 1000 Berlin 17-substituierte estradiene und estratriene
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2605041B2 (ja) * 1987-05-30 1997-04-30 株式会社リコー 感熱記録材料
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TW200938205A (en) 2009-09-16
CN101918427A (zh) 2010-12-15
IL206383A0 (en) 2010-12-30
JP2011507927A (ja) 2011-03-10
CN101918427B (zh) 2013-07-31
AU2008342915A1 (en) 2009-07-09
DOP2010000202A (es) 2010-07-31
KR20100110348A (ko) 2010-10-12
EA201001011A1 (ru) 2011-02-28
PE20091181A1 (es) 2009-09-03
CR11544A (es) 2010-08-27
US20110003779A1 (en) 2011-01-06
DE102007063496A1 (de) 2009-07-02
JP5600070B2 (ja) 2014-10-01
ECSP10010317A (es) 2010-08-31
EP2238148A1 (de) 2010-10-13
US8623850B2 (en) 2014-01-07
AR069963A1 (es) 2010-03-03
PA8809801A1 (es) 2009-07-23
ES2397970T3 (es) 2013-03-12
CA2710486A1 (en) 2009-07-09
ZA201005398B (en) 2012-12-27
BRPI0821667A2 (pt) 2015-06-16
WO2009083271A1 (de) 2009-07-09
CL2008003921A1 (es) 2010-02-12
EP2238148B1 (de) 2012-10-24
CO6321233A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
ECSP045410A (es) Nuevos derivados de piridazin-3(2h)-ona
MX2009006877A (es) Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
SE0301700D0 (sv) Novel compounds
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
CU20100032A7 (es) Depsipéptidos cíclicos
NO20075150L (no) Loselighet av cellulose i ioniske vaesker med tiletning av aminbaser
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
UY29327A1 (es) Derivados de n-(heteroaril)- 1 h- indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica
CL2008003854A1 (es) Compuestos derivados de 2-bencilpiridazinona, inhibidores, reguladores y/o moduladores de met-quinasa; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de un tumor solido, de la sangre o del sistema inmune; kit farmaceutico que comprende una cantidad de dicho compuesto.
CY1110127T1 (el) Υποκατεστημενες 1-προπιολυλο-πιπεραζινες με χημικη συγγενεια για τον υποδοχεα mglur5 για τη θεραπεια καταστασεων πονου
MEP8509A (en) Combination treatment for diabetes mellitus
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
UA96277C2 (en) Benzimidazole derivatives
ATE386534T1 (de) Orale darreichungsform enthaltend probiotische bakterien
UA95715C2 (ru) Фосфадиазиновые производные, фармацевтическая композиция и их применение
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2007002757A1 (es) Compuestos derivados de 1,2,4-triazina sustituida; composicion farmaceutica; y uso en el tratamiento o prevencion del reflujo gastroesofagico y ansiedad.
BRPI0512376A (pt) piperazinodionas como antagonistas de receptor oxitocina
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
DK1541197T3 (da) Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171024